| 2024-04-30 16:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 |
| 2024-04-25 08:06 | UU:VNDA | | News Release200 | Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals |
| 2024-04-22 19:12 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ(TM) ANDA Litigation |
| 2024-04-17 10:21 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan |
| 2024-04-17 09:02 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak |
| 2024-04-02 18:10 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals' Fanapt(TM) (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder |
| 2024-03-06 07:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ(TM) in the Treatment of Insomnia |
| 2024-02-07 16:02 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results |
| 2024-02-05 08:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ ‚ ® in the Treatment of Insomnia |
| 2024-01-31 16:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024 |
| 2024-01-31 09:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis |
| 2024-01-30 12:35 | UU:VNDA | | News Release200 | Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024 |
| 2024-01-29 19:00 | UU:VNDA | | News Release200 | Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024 |
| 2024-01-25 22:05 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY ‚ ® (ponesimod) in the U.S. |
| 2024-01-25 13:07 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology |
| 2024-01-23 09:15 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S |
| 2024-01-19 15:56 | UU:VNDA | | News Release200 | Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration |
| 2024-01-17 15:46 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry |
| 2024-01-12 12:21 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs |
| 2024-01-04 16:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference |
| 2023-12-07 07:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY ‚ ® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis |
| 2023-12-04 18:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis |
| 2023-11-09 16:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences |
| 2023-11-08 16:01 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results |
| 2023-11-01 17:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023 |
| 2023-10-20 07:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ ‚ ® ANDA Litigation |
| 2023-10-05 18:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit |
| 2023-09-06 17:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference |
| 2023-07-27 16:01 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results |
| 2023-07-20 16:30 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023 |
| 2023-06-05 07:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference |
| 2023-06-01 21:41 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Presentations at SLEEP 2023 |
| 2023-06-01 21:31 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S |
| 2023-05-25 07:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness |
| 2023-05-10 14:26 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Responds to Ruling in HETLIOZ ‚ ® ANDA Appeal |
| 2023-05-04 18:00 | UU:VNDA | | News Release200 | Vanda Pharmaceuticals Announces Presentations at DDW 2023 |